President Donald Trump announced Friday that his administration’s TrumpRx prescription drug discount program has added 160 new medications, pushing the total past 800 discounted drugs available to American consumers through the TrumpRx.gov website.
The expansion marks the latest milestone for a program Trump first unveiled in February, one built on agreements with 16 major pharmaceutical companies that accepted tariff-related exemptions in exchange for lowering prices on certain medications and extending discounted pricing to eligible cash-paying consumers.
For millions of Americans who have watched pharmacy costs climb for years, the question has always been simple: why do patients in other countries pay less for the same pills? The TrumpRx program is the administration’s most direct answer yet, and its rapid growth suggests the White House intends to keep pressing the pharmaceutical industry for deeper concessions.
Trump laid out the details in a Truth Social post, as Fox News Digital reported. The president said the program now covers four out of five prescriptions filled by Americans.
“TrumpRx.gov will now provide clear, transparent, and DISCOUNTED offerings for FOUR OUT OF FIVE of every prescription filled by Americans.”
The TrumpRx.gov website lets users search for discounted medications, view estimated savings, and generate coupons for participating prescriptions. The model is straightforward: drugmakers that signed on to “most-favored-nation” pricing arrangements agreed to charge American consumers no more, and ideally less, than what patients in other countries pay for the same drug.
Among the participating companies are Eli Lilly and Novo Nordisk, both of which agreed to reduce prices on popular GLP-1 weight-loss medications. Those drugs have become some of the most talked-about, and most expensive, prescriptions in the country.
The administration’s earlier expansion of TrumpRx added roughly 600 generic drugs to the platform, a move that dramatically widened the program’s reach before Friday’s announcement pushed it past the 800-drug threshold.
Trump made no secret of the mechanism driving these agreements. He credited tariffs as the essential lever that forced pharmaceutical companies to the table.
“Of course, Most Favored Nations would not be possible without my use of TARIFFS, which are getting other Countries to ‘pay up’ instead of relying on American Patients getting ripped off, as they were for decades until I ordered an immediate ‘stop’ to this very unfair and, frankly, foolish situation.”
The structure works like this: drugmakers that participate receive tariff-related exemptions. In return, they agree to lower prices on certain medications and extend those discounts to eligible cash-paying consumers through TrumpRx. The administration finalized these arrangements with 16 major pharmaceutical companies, though the full list of those companies has not been publicly detailed.
Trump claimed the deals have already saved American patients more than $400 million since TrumpRx.gov launched. He said price reductions on some medications have been dramatic.
“Now we are cutting Prices, and cutting them by a LOT, sometimes by 400 or 500 or 600 Percent!”
The methodology behind the $400 million savings figure has not been independently verified or publicly detailed. But the claim itself signals the scale the White House believes the program is operating at, and the political ground it intends to hold on drug pricing.
Trump drew a clear line between what he accomplished in his first term and what he is pursuing now. He described his first-term drug pricing efforts as historic, even if modest in scale.
“I was proud to make History during my First Term when we lowered Drug Prices, even if by a tiny percentage, because this amounted to a HUGE change compared to other presidents only raising Drug Prices, endlessly and significantly, every year.”
The second term, he said, called for something bigger. Most-favored-nation pricing, the principle that Americans should never pay more than consumers in any other country for the same medication, became the centerpiece.
“Then, during my Second Term, I decided to go BIG with Most Favored Nations Pricing, That is to say, we pay no more or, ideally, less than any other Country for the same exact Drug.”
That framing matters. For decades, both parties have talked about drug pricing. Candidates have promised relief. Congressional hearings have produced sharp questions and sharper headlines. But the pharmacy counter kept getting more expensive. The TrumpRx approach bypasses the legislative gridlock entirely, using executive leverage, specifically tariff policy, to extract concessions directly from drugmakers.
The administration has been active on multiple fronts beyond drug pricing. Trump recently defended a $1.8 billion anti-weaponization fund against resistance from Senate Republicans, illustrating the breadth of the executive agenda and the willingness to push past opposition within his own party.
For all the program’s growth, several questions remain open. The administration has not publicly identified all 16 pharmaceutical companies that signed most-favored-nation agreements. The exact terms of the tariff exemptions, what drugmakers gave up, what they received, and how long the arrangements last, have not been fully disclosed.
Eligibility criteria for cash-paying consumers also remain somewhat unclear. TrumpRx.gov functions as a coupon-generation platform, but the specific rules governing who qualifies for discounted pricing at the pharmacy counter have not been laid out in detail.
And the $400 million savings figure, while significant if accurate, lacks a public methodology. How the administration calculated that number, whether it reflects list-price reductions, actual out-of-pocket savings at the register, or some other metric, has not been explained.
None of that diminishes the program’s ambition. But transparency about the mechanics would strengthen the case the White House is making and give consumers clearer information about what they can expect.
The administration has shown a pattern of moving aggressively on executive policy while legal and legislative battles play out elsewhere. A federal judge recently let Trump’s mail-ballot executive order stand, underscoring the administration’s willingness to use executive authority across a range of issues and its track record of surviving legal challenges.
Prescription drug pricing has been a kitchen-table issue for as long as most voters can remember. Americans have watched the same medications sold for a fraction of the price in Canada, Europe, and elsewhere. Congress has held hearings. Pharmaceutical executives have testified. And prices kept rising.
The TrumpRx model represents a different theory of action. Rather than waiting for legislation that never arrives, the administration used trade policy as a crowbar. Tariffs gave the White House leverage. Exemptions gave drugmakers an incentive. And TrumpRx.gov gave consumers a place to find the results.
Whether the program’s growth is sustainable, whether 800 medications become 1,200, whether the savings deepen, whether the pharmaceutical industry pushes back, remains to be seen. Trump made clear Friday that he expects more.
“This is all great news, and I have instructed my Administration to secure more Most Favored Nations Deals, more Partnerships, and Lower Prices for every American Patient.”
Centers for Medicare & Medicaid Services administrator Dr. Mehmet Oz has been involved in the initiative since its early stages. Fox News senior medical analyst Dr. Marc Siegel discussed the program’s potential to reduce costs on “Fox & Friends Weekend.”
The administration has also been pressing forward on immigration enforcement, including shifting USCIS attorneys to the Justice Department to accelerate denaturalization cases, another example of the executive branch moving without waiting for Congress to act.
Meanwhile, major legal questions continue to surround other elements of the Trump agenda, with the president warning the Supreme Court ahead of a birthright citizenship ruling that the consequences of an adverse decision could be severe.
The political class has spent years promising to fix drug prices. Most of those promises died in committee rooms or dissolved into talking points. TrumpRx is not a promise. It is a website with 800 medications, 16 signed agreements, and a claimed $400 million in savings.
Critics will scrutinize the numbers. They should. Transparency strengthens any program built on public trust. But the trajectory is clear: the program launched in February, grew rapidly, and just expanded again. Eli Lilly and Novo Nordisk are at the table. Four out of five prescriptions are covered, by the administration’s count.
For the American patient standing at the pharmacy counter, the question has never been about politics. It has been about the number on the receipt. If TrumpRx keeps driving that number down, the policy will speak for itself, louder than any campaign speech ever could.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.